With the rising cost and time to bring new drugs to market, and the need to increase patient diversity and retention, there is increasing demand for decentralised and hybrid immuno-oncology trials. ICON’s commercial connected health platforms, real-world data and information solutions—together with a global site network, home health services and wearables expertise—enable patient-centric decentralised and hybrid trial solutions.

Late-stage research for immuno-oncology trials introduces unique challenges. ICON’s specialised services can address these through access to large-scale, patient-reported and real-world data, which can be visualised, aggregated, and analysed. In addition, we employ cutting-edge techniques to link clinical trial data to real-world and third-party data without compromising patients’ identity. The compounding power of tokenisation translates to the accumulation of intelligence, so clinical trials can achieve timely regulatory approval and utilise patient data beyond initial investment for pre-approval and commercialisation.

In cardiovascular trials, endpoints are becoming increasingly complex, and endpoint adjudication is becoming a focal point of regulators. With a key opinion leader network of 650 experts, ICON supports consistent reporting across regions and provides a quality control check through the clinical expert review of principal investigator reporting.

Our adaptable, client-oriented team has developed efficient processes to deliver successful results.Our integrated endpoint management capabilities (eCOA, ePRO), include rating-scale licensing through Mapi Research Trust, the holder of over 5,000 COAs and distributor of more than 600 questionnaires.

ICONIK, ICON’s informatics hub, delivers ongoing endpoint quality control, including near-to real-time checks on inter-scale and inter-visit rating plausibility, rating outliers, missing data points, and the dynamic integration of wearables and sensor data to increase the objectivity of measures.